Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab

Transitional Cell Carcinoma

  • Jun Hyuk Hong
  • Seong Jin Kim
  • Isaac Yi Kim
Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_5930-2

Synonyms

Definition

Transitional cell carcinoma (TCC) arises in the urothelium that covers the lining of the renal calyx, renal pelvis, ureter, bladder, and part of the urethra. Although the WHO/ISUP consensus conference has determined that the term urothelial cancer is preferable to the term transitional cell cancer, the latter remains in widespread use. “Urothelial cancer” may also be confusing because cancers of other histological types, such as squamous cancers and adenocarcinoma, also arise in the urothelium.

Characteristics

Epidemiology

It was estimated that in 2007, 67,160 new cases of bladder cancer would be diagnosed and 13,750 patients would die of invasive bladder cancer in the United States. Bladder canceris nearly three times more common in men than in women, and more than 90 % of bladder cancers are TCCs....

Keywords

Bladder Cancer Bladder Tumor Radical Cystectomy Transitional Cell Carcinoma Urothelial Tumor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. Herr HW, Dotan Z, Donat SM et al (2007) Defining optimal therapy for muscle invasive bladder cancer. J Urol 177:437–443CrossRefPubMedGoogle Scholar
  2. Messing EM (2007) Urothelial tumors of the bladder. In: Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA (eds) Campbell-Walsh urology, 9th edn. Saunders-Elsevier, Philadelphia, pp 2407–2446Google Scholar
  3. Sengupta S, Blute ML (2006) The management of superficial transitional cell carcinoma of the bladder. Urology 67:48–54CrossRefPubMedGoogle Scholar
  4. Sternberg CN, Donat SM, Bellmunt J et al (2007) Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Urology 69:62–79CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Division of Urologic OncologyThe Cancer Institute of NJ, Robert Wood Johnson Medical SchoolNew BrunswickUSA
  2. 2.Laboratory of Cell Regulation and CarcinogenesisNational Cancer InstituteBethesdaUSA